Introduction {#s1}
============

Treating atrial fibrillation via catheter ablation has long been established as a safe and effective strategy [@pone.0096331-Verma1]. Recent years have witnessed extraordinary innovation in catheter ablation from conventional manual approach to the robotic-guided navigation system [@pone.0096331-Steven1], [@pone.0096331-Nolker1]. Nonetheless, the benefits of robotic ablation over manual ablation are currently subject to an ongoing debate [@pone.0096331-Smilowitz1]. For example, in a relatively large clinical trial by Thomas et al [@pone.0096331-Thomas1], early use of robotic ablation led to a significant reduction of fluoroscopic time compared with manual ablation, whereas there was no material difference between the two ablations in another clinical trial by Rillig et al [@pone.0096331-Rillig1]. However, it should be noted that the majority of these clinical trials have been seriously underpowered, and some are even nonrandomized. In this context, a meta-analysis represents a powerful statistical methodology for synthesizing research evidence across independent trials [@pone.0096331-Dagres1]. Given the accumulation of data, we sought to design a meta-analysis to compare procedure outcomes between robotic and manual ablations in terms of fluoroscopic time, total procedure duration, radiofrequency time and dose-area product, as well as the success rates of catheter ablation and its major complications in the treatment of atrial fibrillation.

Methods {#s2}
=======

We undertook this meta-analysis of clinical trials in conformity with the guidelines put forth by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement ([Checklist S1](#pone.0096331.s001){ref-type="supplementary-material"}) [@pone.0096331-Moher1].

Search Strategy {#s2a}
---------------

A literature search was conducted of PubMed and EMBASE databases covering the period from the earliest possible year to December 1, 2013, with search terms including "ablation", "robotic", or "navigation", annexed with "atrial fibrillation" or "arrhythmias". In addition, this search was complemented with the perusal of the bibliographies of retrieved original reports and review articles to identify additional eligible articles. Search results were restricted to English-language and clinical trials.

Trial Selection {#s2b}
---------------

Two investigators (F.P. and W.N.) independently read the titles and abstracts to assess their eligibility, and they retrieved the full texts of potentially eligible articles. When necessary, we emailed the corresponding authors to avoid the double counting of study groups involved in more than one clinical trial. Where more than one publication of a clinical trial existed, we extracted data from the most recent or complete publication.

Eligibility Criteria {#s2c}
--------------------

For inclusion, trials had to involve patients needing catheter ablation treatment for atrial fibrillation and compare the changes of either fluoroscopic time, total procedure time, radiofrequency time or dose-area product between robotic and manual ablations. Trials were excluded if they were cross-over trials or conference abstracts or proceedings, case reports or series, editorials, narrative reviews, or non-English articles.

Data Extraction {#s2d}
---------------

Two investigators (F.P. and W.N.) independently extracted data using a standardized Excel template (Microsoft Corp, Redmond, WA). Disagreements were settled by consensus.

For each article, the following data were summarized: the first author\'s surname, year of publication, ethnicity of study patients, sample size of each treatment, fluoroscopic time (minutes), total procedure time (minutes), radiofrequency time (minutes), dose-area product (Gy×cm^2^), the success rate of catheter ablation, and major complication rate between two ablations, as well as the characteristics of trial patients including age, gender, body mass index, atrial fibrillation duration (years), left atrium size (mm), the percentages of paroxysmal atrial fibrillation, left ventricular ejection fraction (LVEF), coronary artery disease (CAD), hypertension and diabetes.

Total procedure time was defined as the time from venous puncture until sheath withdrawal. Radiofrequency time, also known as ablation time, was defined as the time from the first to the last ablation. The success of catheter ablation was defined as complete pulmonary vein isolation, which was confirmed by the disappearance of all pulmonary vein potentials or the dissociation of pulmonary vein potentials from left atrial activity. Major complications referred to adverse events causing either temporary or permanent change in health status requiring intervention.

Diagnosis of hypertension was based on the presence of elevated systolic (≥140 mmHg) and/or diastolic (≥90 mmHg) blood pressure, or current use of antihypertensive medications. Diabetes was defined as fasting plasma glucose levels ≥7.0 mmol/L or non-fasting plasma glucose levels ≥11.0 mmol/L, or taking hypoglycemic drugs or receiving parenteral insulin therapy.

Statistical Analysis {#s2e}
--------------------

For a certain clinical outcome, where data from three or more independent trials were available, a meta-analysis was done. Quantitative outcomes were summarized and compared by weighted mean difference (WMD) with 95% confidence interval (95% CI) between robotic and manual ablations. Categorical variables were compared between the two groups by weighted odds ratio (OR) and its corresponding 95% CI. For each study, weight was calculated as the reciprocal of the variance of the estimated intervention effect. The random-effects model using the DerSimonian & Laird method [@pone.0096331-DerSimonian1] was employed irrespective of the existence of heterogeneity. Heterogeneity across studies was examined with the inconsistency index (*I* ^2^) test, which ranges from 0 to 100% and is defined as the percentage of the observed variability that is due to heterogeneity rather than chance. Given the limited power of *I* ^2^ test for a small number of studies, we considered the presence of heterogeneity at 10% level of significance.

Predefined subgroup analysis was conducted a priori according to study design (randomized and nonrandomized clinical trials). Sensitivity analysis was performed to assess the contribution of individual trials to pooled effect estimates by sequentially omitting each trial one at a time and computing differential estimates for remaining trials. Meta-regression analysis was carried out to evaluate the extent to which different trial-level variables including all characteristics of trial patients as mentioned above explained the heterogeneity of different effect estimates between robotic and manual ablations.

Begg\'s funnel plot was constructed for assessment of publication bias. The asymmetry of this plot was assessed by Egger\'s regression test and then corrected by the trim and fill method with the adjusted effect estimates and number of studies. Also considering the small number of studies involved in this meta-analysis, we considered the presence of publication bias at 10% level of significance for Egger\'s regression test [@pone.0096331-Bowden1]. Statistical analyses were completed with the use of STATA software (StataCorp, College Station, TX, version 11.2 for Windows).

Results {#s3}
=======

Eligible Trials {#s3a}
---------------

The characteristics of study patients involved in all qualified trials are summarized in [Table 1](#pone-0096331-t001){ref-type="table"} and [Table 2](#pone-0096331-t002){ref-type="table"}. The primary search for clinical trials comparing the procedure outcomes between robotic and manual ablations yielded 114 potentially relevant articles published in English language. [Figure 1](#pone-0096331-g001){ref-type="fig"} illustrates a flow diagram schematizing the process of excluding articles with specific reasons. Consequently, 8 articles met our selection criteria and were published from the year 2009 to 2013 [@pone.0096331-Steven1], [@pone.0096331-Thomas1], [@pone.0096331-Rillig1], [@pone.0096331-MalcolmeLawes1]-[@pone.0096331-DiBiase1]. Two of 8 qualified articles recorded outcomes with more than one bipolar voltage of radiofrequency ablation [@pone.0096331-MalcolmeLawes1], [@pone.0096331-Tilz1], resulting in a total of 10 trials in the final analysis.

![Flow diagram of search strategy and study selection.](pone.0096331.g001){#pone-0096331-g001}

10.1371/journal.pone.0096331.t001

###### Baseline characteristics of study patients in qualified studies.

![](pone.0096331.t001){#pone-0096331-t001-1}

  Author (year)                         Country   Random   Number    Age (year)   Gender (Male)   AF duration (year)   BMI (kg/m^2^)   LA size (mm)
  ------------------------------------ --------- -------- --------- ------------ --------------- -------------------- --------------- --------------
  Malcolme-Lawes et al (2013) (30 W)      UK       Yes      10/10    59.3/64.6         NA             3.28/3.48             NA           42.7/38
  Malcolme-Lawes et al (2013) (60 W)      UK       Yes      10/10    60.6/64.6         NA             4.99/3.48             NA           42.5/38
  Thomas et al (2012)                   Germany     No      25/61      60/62        0.64/0.8           4.9/5.5              NA            41/42
  Rillig et al (2012)                   Germany     No      50/20     60/66.5       0.58/0.75             NA             26.7/26.9      47.5/47.5
  Duncan et al (2012)                     UK       Yes      21/23      53/55        0.62/0.61         6.83/6.67             NA              NA
  Tilz et al (2010) (20 W)              Germany     No      10/25      58/61        0.6/0.56           8.3/8.5             26/25          44/44
  Tilz et al (2010) (30 W)              Germany     No      4/25       59/61        0.75/0.56           13/8.5             28/25          48/44
  Steven et al (2010)                   Germany    Yes      30/30      62/61        0.67/0.47            7/6                NA            40/39
  Kautzner et al (2009)                  Czech      No      22/16      55/55        0.73/0.81             NA                NA              NA
  Di Biase et al (2009)                   USA       No     193/197     63/61        0.75/0.74         4.25/4.25            30/30         42.3/44

10.1371/journal.pone.0096331.t002

###### Baseline characteristics of study patients in qualified studies.

![](pone.0096331.t002){#pone-0096331-t002-2}

  Paroxysmal AF (%)    LVEF (%)    CAD (%)    Hypertension (%)   Diabetes (%)   Freedom from AF (%)   Major complications (%)
  ------------------- ---------- ----------- ------------------ -------------- --------------------- -------------------------
  100/100              56.2/52    9.1/11.1       27.3/55.6          0/22.2             50/60                   10/0
  100/100              56.4/52    11.1/11.1      33.3/55.6        11.1/22.2            80/60                    0/0
  76/52                   NA        28/16          72/62              NA                NA                      4/5
  58/60                   NA        14/5           62/75             8/10               NA                      NA
  100/100                 NA         NA              NA               NA                NA                      NA
  NA                      NA         NA            60/72              NA                NA                      NA
  NA                      NA         NA            75/72              NA                NA                      NA
  100/100               68/67       13/7           73/80              NA               73/77                    NA
  100/100                 NA         NA              NA               NA                NA                      NA
  66/69                 58/57       22/21          65/50             8/9              100/68                    2/1

*Abbreviations*: AF, atrial fibrillation; BMI, body mass index; LA, left atrium; LVEF, left ventricular ejection fraction; CAD, coronary artery disease; NA, not available.

Data are expressed as mean values or percentages unless otherwise indicated between robotic and manual ablations.

All 10 qualified trials were conducted in Caucasian populations, and four of them were on a randomized design [@pone.0096331-Steven1], [@pone.0096331-MalcolmeLawes1], [@pone.0096331-Duncan1]. There were respectively total 375 and 417 patients assigned to the robotic ablation and manual ablation procedures in atrial fibrillation treatment. Patients with robotic ablation (mean age: 59.0 years) were younger than those with manual ablation (61.2 years, P = 0.03), and there were no distribution differences for gender and body mass index between the two procedures. The average values of atrial fibrillation duration (6.57 years versus 5.8 years) and left atrium size (43.5 mm versus 42.06 mm) were slightly larger in patients with robotic ablation than with manual ablation group. The percentages of paroxysmal atrial fibrillation, LVEF, CAD, hypertension and diabetes were comparable between the two procedures.

Overall and Subgroup Analyses {#s3b}
-----------------------------

Overall effect estimates for fluoroscopic time, total procedure time, radiofrequency time, and dose-area product, as well as the corresponding subgroup analyses by study design are presented in [Figure 2](#pone-0096331-g002){ref-type="fig"}. Pooling the results of all qualified trials observed significant reductions in fluoroscopic time (minutes) (WMD; 95% CI; P: -8.9; -12.54 to -5.26; \<0.0005) and dose-area product (Gy×cm^2^) (-1065.66; -1714.36 to -416.96; 0.001) for robotic ablation compared with manual ablation, accompanying strong evidence of heterogeneity for both estimates (P\<0.0005) and low probability of publication bias as estimated by the Begg\'s and Egger\'s tests and the visual inspection of funnel plots based on the trim and fill method ([Figure 3](#pone-0096331-g003){ref-type="fig"}). The differences in the magnitude of total procedure time and radiofrequency time were matched between robotic and manual ablations with the presence of heterogeneity ([Figure 2](#pone-0096331-g002){ref-type="fig"}) and the absence of publication bias ([Figure 3](#pone-0096331-g003){ref-type="fig"}).

![Forest plots of changes of fluoroscopic time, total procedure time, radiofrequency time, dose-area product for the comparison of robotic ablation with manual ablation.](pone.0096331.g002){#pone-0096331-g002}

![Filled funnel plots of fluoroscopic time, total procedure time, radiofrequency time, dose-area product for the comparison of robotic ablation with manual ablation.](pone.0096331.g003){#pone-0096331-g003}

In subgroup analyses, great improvement of fluoroscopic time in patients with robotic ablation was consistently seen in both randomized and nonrandomized clinical trials, particularly in the former (WMD; 95% CI; P: -12.61; -15.13 to -10.09; \<0.0005). Moreover, there was no indication of heterogeneity (I^2^ = 0.0%; P = 0.574) and publication bias (data not shown) for randomized clinical trials. As for dose-area product, significant difference was only noticed in randomized trials (-1192.0; -1461.82 to -922.18), which involved only one trial.

Success Rates and Major Complications {#s3c}
-------------------------------------

Success rate of catheter ablation was relatively higher in patients with robotic ablation than with manual ablation (OR; 95% CI; P: 3.45; 0.24 to 49.0; 0.36), the difference yet exhibiting no statistical significance ([Figure 4](#pone-0096331-g004){ref-type="fig"}). Similarly for major complications, robotic ablation approach was associated with slightly high rate compared with manual ablation approach (1.41; 0.38 to 5.21; 0.606), and still the difference was nonsignificant.

![Forest plots of changes of the successful procedure of catheter ablation and the incidence of major complications for the comparison of robotic ablation with manual ablation.](pone.0096331.g004){#pone-0096331-g004}

Sensitivity Analyses {#s3d}
--------------------

Overall, there was not an individual trial influencing the overall effect estimates significantly. After removing each trial and calculating the overall estimates for the remaining trials, the significance of the WMD or OR remained materially unchanged (data not shown).

Meta-Regression Analyses {#s3e}
------------------------

A set of meta-regression analyses were conducted accordingly to explore the extent to which trial-level variables account for heterogeneity among the effect estimates. Unfortunately, none of the examined trial-level confounders contributed to the changes of effect estimates between the robotic ablation and manual ablation approaches (data not shown). It is widely accepted that meta-regression analysis, albeit enabling continuous variables to be considered, does not have the methodological rigor of a properly designed study that is intended to test the effect of these covariates formally.

Discussion {#s4}
==========

To the authors\' knowledge, this is to date the first meta-analysis synthesizing data on the comparison of robotic ablation with manual ablation based on 8 clinical articles and 792 patients for the treatment of atrial fibrillation. The principal finding of this study was the greater reductions of both fluoroscopic time and dose-area product in patients with robotic ablation than with manual ablation, especially in randomized clinical trials. However, caution is urged about the interpretation of these comparisons due to the evident heterogeneity. Moreover, although the success rate of catheter ablation was relatively high by using robotic ablation, significance was not reached likely due to the lack of statistical power or the initial learning stage of this novel technique.

The application of robotic ablation in clinical routine is still in its infancy, and the benefits of this novel technique for catheter ablation in treating atrial fibrillation are unquestionable [@pone.0096331-Willems1], including excellent catheter stability and accuracy of its movement, reduced fluoroscopic time, catheter contact monitoring, improved comfort of the operator during the procedure as they can sit most of the time unexposed to radiation and a very short learning curve potentially allowing for more complicated procedures [@pone.0096331-Jan1]. Various attempts to summarize the existing evidence have been made in recent years, but always in the context of a narrative review of the literature [@pone.0096331-Jan1]-[@pone.0096331-Bai1]. This therefore prompts us to quantitatively assess the superiority of the robotic ablation over the manual ablation in the form of a meta-analysis. Despite approximate 9 minutes in fluoroscopic time were averagely saved in patients with robotic ablation relative to with manual ablation in our findings, total procedure duration remained similar between the two procedures, which is likely attributable to the longer patient prepping time for robotic ablation. This is also understandable because the findings of most enrolled trials were based on the initial experience of robotic ablation systems. More importantly, shorter fluoroscopic time to scattered x-ray is beneficial not only to the operator\'s health during a long interventional career and but also to the patients themselves [@pone.0096331-Picano1], as partly reflected by the reduced dose-area product in our overall analyses. However, this potential benefit might be balanced out by the high costs, increasing the burden of patients. Nevertheless, we believe that with the accumulation of practical evidence, procedures will be greatly improved by using the robotic ablation systems.

However, a note of caution should be added because since heterogeneity in our principle findings might potentially limit the interpretation of the pooled effect estimates. Of note, study design might be a potential source of heterogeneity between trials in the subgroup analyses of this meta-analysis because heterogeneity between trials totally disappeared for fluoroscopic time after restricting analysis to randomized clinical trials. To further account for the contribution of examined trial-level continuous moderators to the overall heterogeneity, we undertook a set of meta-regression analyses, but unfortunately we failed to tease out any contributory factors. It should be noted, however, this meta-regression analysis involves trials of limited sample size, rendering it underpowered to detect a small or moderate effect, and definitively there is a need for further large trials.

Despite the clear strengths of this meta-analysis including the low probability of publication bias, and the robustness of statistical analyses, interpretation of our findings, however, should be viewed in light of several limitations. First, six of ten qualified trials were performed on a nonrandomized design, raising the potential existence of potential biases. On the other hand, although randomized trials can minimize bias and are regarded as the gold standard for quantifying effect estimates, they may not be reflective of patients treated in general clinical practice [@pone.0096331-Piccini1]. Second, there was strong evidence of heterogeneity in a majority of our overall and subgroup analyses, limiting the interpretation of pooled effect estimates. Third, the total sample size of this meta-analysis was not large enough to draw a firm conclusion, such that our findings need to be validated in a large, well-designed clinical trial, and fortunately the ongoing prospective international man-and-machine trial by Rillig et al is designed to fully address the superiority of robotic ablation over manual ablation [@pone.0096331-Rillig2]. Fourth, the fact that study patients were all Caucasians limited the generalizability of our findings, necessitating the future validation in other ethnics. Last but not the least, as with all meta-analyses, despite the low probability of publication bias reported in this meta-analysis, selection bias cannot be completely excluded, since we merely identified articles from the English journals and published trials.

In summary, this study confirmed and extended previous observations by quantifying the great reductions of fluoroscopic time and dose-area product in patients with robotic ablation than with manual ablation, especially in randomized clinical trials. For practical reasons, with the accumulation of data from large randomized clinical trials, successful validation of our findings will revolutionize the current clinical practice and healthcare system by bringing great benefits to doctors and patients alike in the near future.
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